Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.31 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004399 | 0.92 | ESRRA (0.35) | SRD5A2SRD5A1 | |
| SCHEMBL16399270 | 0.92 | SRD5A2 (0.41) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL18004217 | 0.89 | SRD5A2 (0.39) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL18004440 | 0.89 | SRD5A2 (0.39) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL18004327 | 0.89 | NR1H2 (0.40) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL16398931 | 0.89 | SRD5A2 (0.39) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL16399554 | 0.89 | SRD5A2 (0.39) | SRD5A2SRD5A1NR1H2NR1H3QPCT | |
| SCHEMBL18004292 | 0.89 | IDO1 (0.39) | NR1H2NR1H3DHFRDCPS | |
| SCHEMBL18004321 | 0.88 | NR1H2 (0.39) | SRD5A2SRD5A1NR1H2NR1H3 | |
| SCHEMBL18004488 | 0.88 | SRD5A2 (0.47) | SRD5A2SRD5A1NR1H2NR1H3QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SRD5A2 937/4885SRD5A1 764/4885NR1H2 552/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | SRD5A2 937/4885SRD5A1 764/4885NR1H2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.